Julian Harrison
Stock Analyst at BTIG
(4.94)
# 168
Out of 5,044 analysts
504
Total ratings
46.5%
Success rate
39.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterated: Buy | $178 | $41.17 | +332.35% | 23 | Oct 9, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $4.87 | +23.20% | 17 | Oct 5, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterated: Buy | $175 | $88.15 | +98.53% | 18 | Oct 1, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $40 | $15.53 | +157.57% | 28 | Oct 1, 2026 | |
| CLYM Climb Bio | Reiterated: Buy | $32 | $11.00 | +190.91% | 12 | Oct 1, 2026 | |
| LQDA Liquidia | Downgraded: Hold | n/a | $27.38 | - | 48 | Oct 1, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $151 | $82.11 | +83.90% | 14 | Oct 1, 2026 | |
| UTHR United Therapeutics | Upgraded: Buy | $728 | $549.16 | +32.57% | 20 | Oct 1, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $44 | $7.06 | +523.67% | 12 | Sep 29, 2026 | |
| MAZE Maze Therapeutics | Reiterated: Buy | $46 | $27.11 | +69.68% | 8 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.8011 | +399.31% | 15 | Sep 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.87 | +1,049.43% | 8 | Aug 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $132 → $121 | $85.69 | +41.21% | 25 | Aug 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.03 | +385.44% | 9 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.5989 | +567.89% | 22 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 → $77 | $14.39 | +435.09% | 19 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $10.82 | +177.26% | 33 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $13.65 | +324.91% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $21.21 | +98.02% | 5 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $58 | $19.71 | +194.27% | 8 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1 | $0.3499 | +185.80% | 14 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $3.28 | +418.29% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $18.66 | +226.90% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $82 | $143.73 | -42.95% | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $0.799 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.95 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $45.95 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $3.83 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $6.54 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $2.87 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.0001 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $28.51 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $0.9163 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $1.02 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $3.52 | n/a | 1 | Dec 9, 2020 |
Nektar Therapeutics
Oct 9, 2026
Reiterated: Buy
Price Target: $178
Current: $41.17
Upside: +332.35%
Rezolute
Oct 5, 2026
Reiterated: Buy
Price Target: $6
Current: $4.87
Upside: +23.20%
ABIVAX Société Anonyme
Oct 1, 2026
Reiterated: Buy
Price Target: $175
Current: $88.15
Upside: +98.53%
Cullinan Therapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $40
Current: $15.53
Upside: +157.57%
Climb Bio
Oct 1, 2026
Reiterated: Buy
Price Target: $32
Current: $11.00
Upside: +190.91%
Liquidia
Oct 1, 2026
Downgraded: Hold
Price Target: n/a
Current: $27.38
Upside: -
Oruka Therapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $151
Current: $82.11
Upside: +83.90%
United Therapeutics
Oct 1, 2026
Upgraded: Buy
Price Target: $728
Current: $549.16
Upside: +32.57%
Cartesian Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $44
Current: $7.06
Upside: +523.67%
Maze Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: $46
Current: $27.11
Upside: +69.68%
Sep 14, 2026
Reiterated: Buy
Price Target: $4
Current: $0.8011
Upside: +399.31%
Aug 27, 2026
Reiterated: Buy
Price Target: $10
Current: $0.87
Upside: +1,049.43%
Aug 26, 2026
Rated: Buy
Price Target: $132 → $121
Current: $85.69
Upside: +41.21%
Aug 19, 2026
Reiterated: Buy
Price Target: $5
Current: $1.03
Upside: +385.44%
Aug 14, 2026
Reiterated: Buy
Price Target: $4
Current: $0.5989
Upside: +567.89%
Aug 10, 2026
Reiterated: Buy
Price Target: $74 → $77
Current: $14.39
Upside: +435.09%
Aug 10, 2026
Reiterated: Buy
Price Target: $30
Current: $10.82
Upside: +177.26%
Aug 6, 2026
Reiterated: Buy
Price Target: $58
Current: $13.65
Upside: +324.91%
Aug 5, 2026
Reiterated: Buy
Price Target: $42
Current: $21.21
Upside: +98.02%
Aug 3, 2026
Initiated Coverage: Buy
Price Target: $58
Current: $19.71
Upside: +194.27%
Mar 19, 2026
Reiterated: Buy
Price Target: $1
Current: $0.3499
Upside: +185.80%
Feb 20, 2026
Reiterated: Buy
Price Target: $17
Current: $3.28
Upside: +418.29%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $18.66
Upside: +226.90%
Nov 3, 2025
Reiterated: Buy
Price Target: $82
Current: $143.73
Upside: -42.95%
Mar 31, 2025
Reiterated: Buy
Price Target: $14
Current: $0.799
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $11.95
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $45.95
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $3.83
Upside: n/a
Nov 13, 2024
Reiterated: Buy
Price Target: $24
Current: $6.54
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $2.87
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.0001
Upside: n/a
Apr 28, 2021
Reiterated: Buy
Price Target: $12
Current: $28.51
Upside: n/a
Apr 27, 2021
Reiterated: Buy
Price Target: $29
Current: $0.9163
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $1.02
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $3.52
Upside: n/a